Search our team at AdventHealth Research Institute
-
NCT06492616
STML-ELA-0422 Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaIn this study, we are testing a new endocrine therapy, called elacestrant, that is an endocrine therapy that stops hormones from attaching to cancer cells and helping them grow. Researchers would like...
-
NCT05629585
D926XC00001: Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have Residual Invasive Disease in Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection (TROPION-Breast03)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaWe are doing this study to learn more about whether an investigational drug called datopotamab deruxtecan (also called Dato-DXd), either alone or in combination with another investigational drug...
-
NCT05929768
S2212, SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), A RANDOMIZED PHASE III STUDY
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis is a randomized Phase III trial comparing a standard neoadjuvant chemotherapy regimen to an experimental neoadjuvant chemotherapy regimen that omits AC therapy. Both arms receive pembrolizumab...
-
NCT05633654
GS-US-595-6184 A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63; NCT05633654)
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer Research -
NCT06065748
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is not currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to compare the effects, good or bad, of two hormonal treatments, giredestrant and fulvestrant, both given in combination with your study doctor’s choice of a class of...
-
NCT03723928
S1703, Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
This study is currently enrolling.Research Area: Rocky Mountain Cancer ResearchThis randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread...
-
NCT05812807
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT5616104
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Study)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to create a large-scale, population-based database. This database will match health information with genome data to potentially identify new gene associations in breast...
-
NCT5812807
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT06188559
BB-1701-G000-205 An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to determine if a new drug called BB-1701 is safe and effective in people who have HER2-positive or HER2-low, unresectable or metastatic breast cancer (MBC). There are two...
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...